Arizona State Retirement System Grows Stock Position in Schrödinger, Inc. (NASDAQ:SDGR)

Arizona State Retirement System increased its position in shares of Schrödinger, Inc. (NASDAQ:SDGR – Get Rating) by 3.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 16,627 shares of the company’s stock after buying an additional 628 shares during the quarter. Arizona State Retirement System’s holdings in Schrödinger were worth $311,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Commonwealth Equity Services LLC increased its position in shares of Schrödinger by 79.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 137,919 shares of the company’s stock worth $2,577,000 after acquiring an additional 61,071 shares during the period. LPL Financial LLC increased its holdings in Schrödinger by 25.9% in the fourth quarter. LPL Financial LLC now owns 20,846 shares of the company’s stock valued at $390,000 after buying an additional 4,282 shares in the last quarter. Arete Wealth Advisors LLC purchased a new position in shares of Schrödinger during the 4th quarter worth approximately $9,582,000,000. SG Americas Securities LLC increased its stake in shares of Schrödinger by 163.5% during the 4th quarter. SG Americas Securities LLC now owns 23,657 shares of the company’s stock worth $442,000 after purchasing an additional 14,679 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Schrödinger by 21.1% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,887 shares of the company’s stock worth $241,000 after acquiring an additional 2,249 shares during the period. Hedge funds and other institutional investors own 68.70% of the company’s stock.

Schrödinger Price Performance

NASDAQ SDGR opened at $38.95 on Tuesday. Schrödinger, Inc. has a 12 month low of $15.85 and a 12 month high of $39.31. The firm has a market capitalization of $2.77 billion, a PE ratio of 299.64 and a beta of 1.06. The company’s 50 day simple moving average is $27.79 and its 200 day simple moving average is $23.57.

Schrödinger (NASDAQ:SDGR – Get Rating) last released its quarterly earnings results on Tuesday, February 28th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.11. The business had revenue of $56.84 million for the quarter, compared to analyst estimates of $48.69 million. Schrödinger had a net margin of 7.30% and a negative return on equity of 27.77%. Sell-side analysts anticipate that Schrödinger, Inc. will post 0.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Morgan Stanley lifted their target price on shares of Schrödinger from $38.00 to $39.00 and gave the company an “equal weight” rating in a report on Friday, March 10th. Piper Sandler began coverage on shares of Schrödinger in a research report on Friday, May 5th. They issued an “overweight” rating and a $60.00 target price for the company. Citigroup dropped their target price on shares of Schrödinger from $52.00 to $50.00 in a research report on Monday, May 8th. Finally, BMO Capital Markets dropped their target price on shares of Schrödinger from $83.00 to $78.00 and set an “outperform” rating for the company in a research report on Wednesday, March 1st. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $50.00.

Schrödinger Company Profile

(Get Rating)

Schrödinger, Inc, together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries.